目的 探讨miRNA-126与runt相关转录因子3(RUNX3)在支气管哮喘患儿中的表达及意义.方法 选取河南省儿童医院收治的80例支气管哮喘患儿为研究对象,根据疾病的临床进展分为急性期组(n=42)与缓解期组(n=38);同期选取健康体检的儿童40例为对照组.qRT-PCR法检测3组受试儿外周血中miRNA-126水平,Western blot检测RUNX3蛋白表达水平;分析哮喘组患儿miRNA-126与RUNX3水平的相关性;ROC曲线分析miRNA-126及RUNX3在哮喘中的诊断价值.结果 与对照组相比,缓解期组与急性期组的miRNA-126表达水平均显著增加(P<0.05),RUNX3蛋白水平显著降低(P<0.05);且急性期组miRNA-126水平显著高于缓解期组,RUNX3水平显著低于缓解期组(P<0.05);miRNA-126与RUNX3水平呈显著负相关(P<0.05);miRNA-126与RUNX3诊断哮喘的AUC分别为0.933,0.847,诊断哮喘临床分期的AUC分别为0.696,0.798.结论 miRNA-126与RUNX3可能协同参与儿童支气管哮喘的发生发展,可作为哮喘诊断及病情评估的潜在辅助指标.

目的:探讨外周血中性粒细胞与淋巴细胞比值(NLR)在儿童化脓性脑膜炎(PM)预后中的意义.方法:收集2020年5月—2021年5月我院收治的PM患儿80例,并根据严重程度分为轻症组(48例)和重症组(32例),根据预后结局分为预后良好组(61例)和预后不良组(19例);收集同期体检的健康儿60例为健康组;检测两组患儿中性粒细胞(N)、淋巴细胞(L)百分比及二者的比值(NLR);采用多因素Logistic回归分析患儿预后不良的危险因素;ROC曲线分析NLR诊断患儿预后的效能.结果:轻症组和重症组患儿NLR均显著高于健康组(P<0.05),且重症组高于轻症组(P<0.05);预后不良组NLR显著高于预后良好组(P<0.05);多因素分析结果显示,年龄、惊厥、脑脊液糖、外周血NLR均是PM患儿预后的影响因素(P<0.05);ROC曲线分析显示,NLR评估PM患儿预后的曲线下面积为0.743,最佳截断值为2.44,敏感度为81.97％,特异度为78.95％,约登指数为0.609.结论:外周血NLR水平与PM患儿病情及预后有关,高水平NLR是患儿预后不良的危险因素.

Aim: To explore the relation between the plasma concentration of 5-fluorouracil(5-FU) and the efficacy and safety of S-1 plus paclitaxel as chemotherapy in patients with advanced gastric cancer.Methods: A total of 78 advanced gastric cancer patients receiving S-1 plus paclitaxel chemotherapy were collected.The plasma concentration of 5-FU was examined at each cycle of chemotherapy.The relation between plasma concentration of 5-FU and the efficacy and safety of the chemotherapy was assessed.Results: The median plasma concentration of 5-FU was 150 μg/L.The patients were allocated into Group A(plasma concentration of 5-FU≥150 μg/L, n=40) and Group B(plasma concentration of 5-FU<150 μg/L, n=38).Significant differences were observed in response rate(50.0% vs 18.4%, P<0.05) and disease control rate(82.5% vs 65.8%, P<0.05).The myelosuppression and mucositis in Group A was more severe than those in Group B (P<0.05).There were no significant differences between Group A and Group B in nausea,vomiting and diarrhea(P>0.05).Conclusion: For advanced gastric cancer patients receiving S-1 and paclitaxel as chemotherapy, those with the plasma concentration of 5-FU≥150 μg/L can obtain better survival benefit, but the severity of myelosuppression and mucositis will increase at the same time.

Aim: To observe the efficacy and safety of raltitrexed plus oxaliplatin in the treatment of advanced colorectal cancer as the second-line treatment.Methods: A total of 57 advanced colorectal cancer patients with failed first-line chemotherapy were randomized into two groups,28 patients treated with TOMOX and 29 patients treated with FOLFOX4.The differences in treatments effect and adverse reaction between the two groups were compared.Results: The response rates were 14.3%(4/28) in TOMOX group and 10.3%(3/29) in FOLFOX4 group, the disease control rates were 78.6%(22/28) in TOMOX group and 82.7%(24/29) in FOLFOX4 group(P>0.05).The progression-free survival was 8.30 and 8.10 months for TOMOX group and FOLFOX4 group,and the overall survival was 15.40 and 14.10 months,respectively(P>0.05).The patients in TOMOX group had significantly lower incidence of neutropenia and cardiotoxicity,while the incidence of hepatic disorder was higher,which was endurable,however(P<0.05).Conclusion: Raltitrexed combined with oxaliplatin is more effective with less side effect as the second-line treatment for advanced colorectal cancer.

目的 探讨锌指蛋白217基因(ZNF217)在食管鳞癌侵袭转移中的作用.方法 合成ZENF217基因的siRNA序列并转染对数生长期食管鳞癌EC9706细胞.设置转染无义序列siRNA和未转染EC9706细胞为阴性对照和空白对照.半定量RT-PCR和Western blot方法分别检测转染48 h后3组细胞ZNF217 mRNA和蛋白的表达变化;侵袭小室检测3组细胞穿膜细胞数变化;MTT法分析3组细胞增殖能力的变化.结果 与空白对照组和阴性对照组比较,转染ZNF217 siRNA组EC9706细胞ZNF217 mRNA和蛋白表达均显著下降,差异有统计学意义(P＜0.05);转染ZNF217 siRNA组EC9706细胞穿膜细胞数显著下降,差异有统计学意义(P ＜0.05);ZNF217 siRNA能明显抑制EC9706细胞体外增殖能力(P＜0.05).结论 ZNF217基因表达下降能显著抑制EC9706细胞体外侵袭力和增殖能力,ZNF217基因有望成为食管癌基因治疗的有效靶点.